B-Body_Cartoon-Camera_5

Bispecific Antibody Discovery

The molecule you engineer is the molecule you manufacture

B-Body® Discovery is bispecific from day one. We design molecules for affinity, epitope, geometry, and developability together, not as a sum of separately optimized monoclonals. You get a lead candidate ready for cell line development.

Get a quote Download data sheet »
Yes

In the clinic?

288+

numbers of B-Bodies screened in a typical campaign

4

Months from binder to lead candidates

CLD

Ready for cell line development

The B-Body® platform Bispecific antibody discovery in the final therapeutic format

B-Body Discovery takes you from binding arms to a manufacturing-ready bispecific. Start with arms from any source, whether ours, yours, or the public domain, and we build and screen them as bispecifics in their final format, not as monoclonals you reformat later.

Bispecific biology has its own rules. We don’t stick two antibodies together and hope it works. We explore a large design space across affinities, epitopes, and geometries, then let the data pick the combination that performs. We want the biology to win.

Because every molecule is screened in its final format, the lead you choose is the molecule you manufacture. Developability is built in, so it moves toward cell line development without a separate optimization step.

What the B-Body® platform delivers
Two binding arms from any source, assembled on a scaffold that solves chain mispairing by design.
No VHHs, scFvs, or common light chains required.
Compatibility with diverse human germlines, both kappa and lambda light chains, standard Fc modifications, and ADC conjugation, across 1×1, 2×1, and 2×2 geometries.

Advantages Speed and risk reduction. Not one or the other.

Most bispecific platforms force a choice. Single-chain shortcuts make front-end work faster but stack downstream costs you’ll pay later in CMC, immunogenicity, and protein engineering. Exploring the full design space is more thorough but takes more time. B-Body™ is built for both.

Speed

No lead optimization detour

Because the design space is screened in the final therapeutic format with developability built in, the lead doesn’t need a separate optimization phase.

The molecule you select is the molecule that goes to manufacturing. No format engineering. No second round of expression to confirm the candidate still works once it’s rebuilt.

Risk Reduction

Engineered for the full development cycle

Single-chain approaches take shortcuts that look fast on paper but carry a higher burden later: CMC headaches, immunogenicity risk, and expensive protein engineering to clean up what should have been right the first time.

We design and screen with downstream stability in mind, so the molecule you pick is a molecule you can actually develop.

Binder to lead in 4 months with developability by design
  • Rapid discovery and expression of high-quality bispecific antibodies
  • No need for common light chains. Our platform solves mispairing by design
  • Use your existing variable domains or access ours for plug-and-play flexibility
  • Proprietary human-like phage libraries deliver diverse, developable binders
  • Validated, flexible geometries (1×1, 2×1, 2×2) available to adapt to your project requirements
  • Drug-like molecules delivered, ready for cell line development

How it works Inside the full discovery process

One continuous process of discovery, expression, and characterization that takes a target antigen all the way to a panel of ranked, manufacturable bispecific leads.

B-Body® Discovery starts before any wet work. We work side by side with your team to build a winning Target Product Profile. Then our collaborative process takes you from raw phage libraries to a ranked panel of bispecific leads. Each stage runs standard assays, with optional characterization add-ons you can layer in.

inv-AdobeStock_928707447-crop

Teamwork ensures project success

3 weeksPhage Selection and Amplification

Upfront work

  • You bring your target and ideas
  • We co-design a Target Product Profile with your team, defining biological goals, design constraints, and what success looks like upfront.
  • Our experienced protein engineering scientists work with your team to design a fully optimized project plan based on your criteria
  • Programs can emphasize affinity, epitope, geometry, and valency to drive a coordinated response
  • You get decades of expertise added to your team before you spend a dime
inv-Graphic-BBodyDiscovery-Step2-01

Phage selection & amplification
Screen against phage libraries → stringent wash & elute binders → phage amplification. Fully automated selection advances top clones; >30 libraries screened, >10⁹ primary clones per library

Next-generation libraries empower binder discovery

3 weeksPhage Selection and Amplification

Next-Gen libraries widen the net

  • Optimizes germline frameworks for clinical success
  • Represents a diverse array of human germlines
  • Offers natural CDR diversity and pairings with minimal liabilities
  • Searches against >30 proprietary phage libraries with >10⁹ primary clones per library

Selection & amplification advances top clones

  • Screens across up to 3 conditions. >90 unique screens run in parallel to identify mAb candidates
  • Assesses a wide range of affinities (KDs) and epitope diversities
  • Delivers high developability and human-likeness
inv-Graphic-BBodyDiscovery-Step3-01

Clonal mAb production
Reformatting to IgG → clonal mAb expression → robotic mAb purification, then data analysis & ranking → single-point cell binding → HT mAb SPR affinity assays

Reformat, express and purify top binders

3 weeksClonal mAb Production

Develop the monoclonal antibodies

  • The best bispecifics start with a strong consideration set of monoclonal antibodies
  • Top leads are formatted into mAbs, expressed and purified
inv-Graphic-BBodyDiscovery-Step4-01

Rapid in vitro characterization
Leading mAbs characterized for affinity, kinetics, cross-reactivity, and DNA sequence

Determine affinity, kinetics, cross-reactivity and DNA sequence

3 weeksIn Vitro Characterization

Run assays to characterize mAbs

  • Full binding kinetics for human and cynomolgus antigen on up to four 96-well plates
  • Y/N cell binding to one cell line on up to four 96-well plates
inv-Graphic-BBodyDiscovery-Step5-01

B-Body antibody expression matrices.
A >250-permutation matrix of B-Body® bispecifics is expressed and 1-step affinity purified to yield a test panel. Top mAbs are formatted in the B-Body® platform; optimally performing bispecifics are identified by high-throughput gating assays. Partner-supplied mAb panels can enter here.

Explore the maximum design space to create an optimized bispecific

2 monthsB-Body® Matrix: Expression, Purification & Characterization

B-Body matrix evaluates potential candidates 

  • 12×12 B-Body expression matrix in 2 orientations, including >250 permutations
  • Single-step CH1 affinity purification

Characterization helps you score

  • Y/N cell binding
  • Single-concentration functional assay
  • Capillary electrophoresis
  • Size exclusion chromatography (SEC)
  • Polyreactivity
  • AC-SINS
Group 2129

Select top B-Body bispecific candidates

3 weeksSelection

Test and select the best candidates

  • Collaborative review to select top 10-15 candidates
  • Scale and express top candidates 
  • Perform functional assays to inform final selection
  • Top leads and data package are ready to move into IND-enabling studies

Optional add-ons Get deeper characterization

Most programs add structured characterization beyond what’s included in the matrix screening: biophysical, binding kinetics, and formulation. We run all of it in-house. You don’t need another outsourced partner or potential in-house lab delays.

See all add-on services
Cell Binding Example

BIO

Full biophysical + binding suite

Carterra LSA high-throughput binding kinetics and epitope diversity, validated cell binding analysis, in silico liability scanning, mass spec for intact mass confirmation, full developability assay panel, and high-concentration formulation optimization.

devreport-card

DEV

Extensive developability capabilities

Expression and purity, thermal stability, self-association, aggregation, solubility, immunogenicity risk, viscosity, each measured with a validated technique. The full developability data sits behind every lead candidate we hand off.

TOTAL BISPECIFIC FLEXIBILITY Use the best mAbs for your target, no matter the source

Most bispecific programs are constrained by where the binders come from. Ours aren't. You can plug in antibodies from four different paths and our process handles the rest.

inv-WebsiteAssets-ForClient-1

Path 1

We discover them for you

Run our mAb Discovery service to generate fully-human binders against your targets, then move them into the B-Body® matrix.

Path 2

You bring your own

If you already have binders in hand from your own discovery, a previous partner, or another program, we can take those sequences directly into the B-Body® matrix.

Path 3

Public-domain antibodies

Clinical-stage and published antibodies work in the matrix. We’ve validated the platform with diverse germlines from public sources.

path 4

Our internal collection

Coming soon!

Get in touch

TRANSPARENT PRICING Each project is customized. The pricing is structured.

B-Body® Discovery is scoped in stages so you only pay for the parts you need. If you’re bringing your own binders, you skip Stage 1. If you need additional characterization data, we can add that to your project. You can take a clinical license any time prior to submitting your IND. Licensing waits until you’re ready.

$100k-$400kUSD

Stage 1: mAb Sourcing

Use our mAb Discovery service to generate fully-human binders. Skip this stage if you’re bringing your own.

$500kUSD

Stage 2: Bispecific Discovery

Matrix expression, purification, characterization, screening, and consultative lead selection. You get and own 10 leads.

roland-green
Roland Green CEO and Founder, Invenra

We spent over 15 years building antibody engines that probe the maximum design space, so you’re not choosing from a handful of candidates; you’re choosing from the best ones. Monoclonals, bispecifics, and trispecifics are all screened in the format you’d manufacture, all ready to advance. That’s what we mean by simple. Not less work on our end. More certainty on yours.”

Frequently Asked Questions Quick answers to initial questions

Who owns the sequences at the end of the project?

You do!

Do we pay milestones and royalties?

No. You pay for the clinical/commercial license for each candidate and there are no milestone or royalty payments on the resulting molecules.

Do we get all the developability data?

Yes. We hand off the full data package on every candidate that comes through the matrix, not just the final leads.

Who picks the final lead candidates?

You do, in consultation with our team. Don’t worry, this isn’t a black box process. We share all the data with you and help work through the selection together. Your science, your decision.

What's our involvement during the project?

You help us plan the project up front (Target Product Profile, biological goals, design constraints). We hold regular progress update meetings throughout. At the end, we share the data, and you select the best lead candidate.

What if we don't know whether a bispecific or trispecific is the right approach?

We can help you make that decision. Many of our clients start with the bispecific. If later we decide a trispecific is a better approach, the data we collect during B-Body™ screening informs a future trispecific program if your biology suggests three arms would work better. The work isn't wasted either way.

How long does this take?

It depends on the complexity of the program. The shortest engagements run a few weeks. More involved programs run several months.

Dive deeper Related services and resources

Platform explainer

The B-Body® Platform

Already have Fab arm sequences? Skip discovery. We express and purify.

Learn more

Find mAbs first

mAb Discovery

Generate fully-human binders for your targets before they enter the B-Body matrix.

Learn more

Expression only

B-Body® Express

Already have your sequences? Skip discovery and have them assembled and expressed.

Learn more

Three targets

T-Body™ Discovery

Trispecific discovery programs with three binding arms and more complex biology.

Learn more

Program Spotlights A growing list of satisfied scientists

Ronnekleiv-Kelly_Sean_400px-1
Sean Ronnekleiv-Kelly, MDSurgical Oncology, University of Wisconsin SMPH

“The team at Invenra is highly professional, timely with milestones, demonstrate clear expertise and scientific rigor, and offer an extraordinarily unique platform that has yielded high-confidence results, despite an exceedingly challenging target.”

headshot
Ravi V. Kolla, PhDImmunologist and B.D. Professional

“Invenra and its technology are top-notch. I have and will continue to recommend the Invenra team to anyone seeking novel antibody discovery, bispecific and trispecific antibody development, and novel ADC development.”

inv-Avatar
CEOStartup in Stealth Mode

"Top-tier platform combined with top-tier people. A team that has collaborated to drive our programs forward with speed and scientific rigor, even providing services like specialized in vitro assays and efficacy models."

inv-Avatar
CEOStartup in Stealth Mode

"The level of customization and partnership support is unparalleled relative to the other groups we evaluated for our company."

inv-Avatar
VP R&DTop-Tier CDMO

“We have worked with over 20 platforms, and the B-Body was the highest-yielding, easiest to work with bispecific platform.”

Get in touch Let’s talk about your bispecific program.

Tell us about your targets and goals. A scientist from our team will get back to you — typically within 1 business day.

Your information is 100% confidential.

We don't share your data with third parties, add you to marketing lists without permission, or contact you about anything other than this request. Target biology is treated as confidential. Need an NDA first? Just say so. We'll send one over.